Returns On Capital At Shandong Pharmaceutical GlassLtd (SHSE:600529) Have Hit The Brakes

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. That's why when we briefly looked at Shandong Pharmaceutical GlassLtd's (SHSE:600529) ROCE trend, we were pretty happy with what we saw.

Return On Capital Employed (ROCE): What Is It?

Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. Analysts use this formula to calculate it for Shandong Pharmaceutical GlassLtd:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.12 = CN¥916m ÷ (CN¥9.6b - CN¥1.8b) (Based on the trailing twelve months to March 2024).

So, Shandong Pharmaceutical GlassLtd has an ROCE of 12%. On its own, that's a standard return, however it's much better than the 6.4% generated by the Medical Equipment industry.

See our latest analysis for Shandong Pharmaceutical GlassLtd

Above you can see how the current ROCE for Shandong Pharmaceutical GlassLtd compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Shandong Pharmaceutical GlassLtd for free.

What The Trend Of ROCE Can Tell Us

The trend of ROCE doesn't stand out much, but returns on a whole are decent. The company has consistently earned 12% for the last five years, and the capital employed within the business has risen 113% in that time. 12% is a pretty standard return, and it provides some comfort knowing that Shandong Pharmaceutical GlassLtd has consistently earned this amount. Over long periods of time, returns like these might not be too exciting, but with consistency they can pay off in terms of share price returns.

Our Take On Shandong Pharmaceutical GlassLtd's ROCE

The main thing to remember is that Shandong Pharmaceutical GlassLtd has proven its ability to continually reinvest at respectable rates of return. However, over the last five years, the stock has only delivered a 6.6% return to shareholders who held over that period. That's why it could be worth your time looking into this stock further to discover if it has more traits of a multi-bagger.

Shandong Pharmaceutical GlassLtd could be trading at an attractive price in other respects, so you might find our free intrinsic value estimation for 600529 on our platform quite valuable.

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.